Phase 1 - Pharmacyte Biotech Inc research using Melligen Cells

Project Member(s): Simpson, A.

Funding or Partner Organisation: Pharmacyte Biotech Inc

Start year: 2015

Summary: This is a first phase engagement with Pharmacyte Biotech Inc (a US based cell therapy company formerly known as Nuvilex) around investigating the in vitro and in vivo performance of UTS technology (Melligen Cells for diabetes treatment) once encapsulated. Future phases may result in more detailed in vitro and in vivo studies investigating the encapsulated Melligen cells.

Keywords: Pharmacyte, Pharmacyte Biotech, Nuvilex, Melligen, Diabetes, Simpson

FOR Codes: Clinical Sciences, Regenerative Medicine (incl. Stem Cells and Tissue Engineering), Diabetes, Regenerative medicine (incl. stem cells), Clinical health

Acknowledgement of Country

UTS acknowledges the Gadigal people of the Eora Nation, the Boorooberongal people of the Dharug Nation, the Bidiagal people and the Gamaygal people, upon whose ancestral lands our university stands. We would also like to pay respect to the Elders both past and present, acknowledging them as the traditional custodians of knowledge for these lands.